{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:59:26Z","timestamp":1781499566567,"version":"3.54.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite advances in treating multiple myeloma, the management of patients with relapsed or refractory disease remains a major clinical challenge. The increasing use of novel agents in frontline therapy has led to a growing population refractory to key drugs such as lenalidomide and daratumumab, resulting in limited effective options in subsequent lines. Moreover, the increasing prevalence of double-refractory cases highlights a challenge with limited evidence guiding treatment choice. In Italy, the anticipated introduction of innovative immunotherapies offers new hope, yet their real-world impact remains uncertain. This study aimed to establish expert consensus on current challenges, emerging therapies, and address unmet needs in the Italian clinical landscape.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A modified Delphi process was employed to reach consensus regarding the current and future management of relapsed\/refractory multiple myeloma in Italy. One hematology expert served as opinion leader, while a panel of eight experts participated in two rounds of online surveys and a final virtual consensus meeting. Panelists were blinded to others throughout the process. In each survey round, experts provided their level of agreement on statements regarding epidemiology of multiple myeloma in Italy, treatment patterns in clinical practice, and unmet needs in second and subsequent therapy lines. The final meeting allowed discussion and consolidation of responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most statements (28\/31, 90%) achieved consensus after two Delphi rounds, while three required further discussion and agreement in the final meeting. Experts reached consensus on the epidemiology of multiple myeloma in Italy and preferred treatment patterns for relapsed\/refractory disease. They consistently highlighted the limited efficacy and safety of available second- and third-line therapies for relapsed\/refractory multiple myeloma, regardless of prior exposure, recognizing a substantial unmet clinical need due to the lack of satisfactory options, particularly in specific populations including double-refractory patients to lenalidomide and anti-CD38 agents. The anticipated introduction of innovative immunotherapies was identified as a promising opportunity to address these gaps and improve outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite multiple available agents and combinations, effective treatment of all patients with relapsed\/refractory multiple myeloma remains a major unmet need. Given their distinct mechanism of action, immunotherapies hold significant potential to address this gap and improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1756247","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:22:29Z","timestamp":1770960149000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Addressing unmet needs in relapsed\/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies"],"prefix":"10.3389","volume":"16","author":[{"given":"Michele","family":"Cavo","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[{"name":"Division of Hematology, Azienda Ospedaliera (AO) Santa Croce e Carle di Cuneo","place":["Cuneo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Buda","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa (UO) Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Azienda Ospedaliero-Universitaria Pisana (AOUP)","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Hematology Division, Azienda Ospedaliero-Universitaria (AOU) \u201cPoliclinico-S. Marco\u201d, University of Catania","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area, \u201cAldo Moro\u201d University School of Medicine","place":["Bari, Italy"]},{"name":"Unit of Hematology and Stem Cell Transplantation, Azienda Ospedaliero-Universitaria Consorziale (AOUC) Policlinico","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[{"name":"Hematology Clinic Stem Cell Transplant Unit at Azienda Ospedaliero-Universitaria (AOU) delle Marche","place":["Ancona, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Petrucci","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera-Universitaria Policlinico Umberto I","place":["Roma, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[{"name":"Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Ser\u00e0gnoli Institute of Hematology","place":["Bologna, Italy"]},{"name":"Department of Medical and Surgical Sciences, Bologna University","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[{"name":"Hematology, Padua University School of Medicine","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Berruto","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Solutions Italy S.R.L.","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Freddi","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Solutions Italy S.R.L.","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"La Malfa","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Solutions Italy S.R.L.","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"B1","unstructured":"Ferlay\n              J\n            \n            \n              Ervik\n              M\n            \n            \n              Lam\n              F\n            \n            \n              Laversanne\n              M\n            \n            \n              Colombet\n              M\n            \n            \n              Mery\n              L\n            \n          \n          Lyon, France\n          International Agency for Research on Cancer\n          Global Cancer Observatory: Cancer Today\n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"22099","DOI":"10.1038\/s41598-020-79176-3","article-title":"National burden of cancer in Italy, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"10","author":"Bosetti","year":"2020","journal-title":"Sci Rep"},{"key":"B3","unstructured":"I numeri del cancro in Italia\n          \n          \n          2024"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.331","article-title":"Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time","volume":"32","author":"Kumar","year":"2018","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16674","article-title":"Incidence and survival of multiple myeloma: a population-based study of 10\u2013524 patients diagnosed 1982-2017","volume":"191","author":"Langseth","year":"2020","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13523","article-title":"Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database","volume":"106","author":"Scheid","year":"2021","journal-title":"Eur J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0023","article-title":"Multiple myeloma, version 1.2025. Featured updates to the NCCN guidelines\u00ae","volume":"23","author":"Kumar","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B9","unstructured":"Multiple Myeloma"},{"key":"B10","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-023-00804-y","article-title":"Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/cancers15010155","article-title":"How to manage patients with lenalidomide-refractory multiple myeloma","volume":"15","author":"de Arriba de la Fuente","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/cancers17071168","article-title":"Forcing ahead: second-line treatment options for lenalidomide-refractory multiple myeloma","volume":"17","author":"Mancuso","year":"2025","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000975","article-title":"Management and outcomes of anti-CD38 refractory patients: the impact of retreatment and of subsequent therapies","volume":"7","author":"Kastritis","year":"2023","journal-title":"HemaSphere"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000444","article-title":"Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line","volume":"2023","author":"Hartley-Brown","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.clml.2024.12.002","article-title":"Real-world treatment patterns and clinical outcomes in patients with multiple myeloma previously treated with lenalidomide and an anti-CD38 monoclonal antibody","volume":"25","author":"Ramasamy","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B19","unstructured":"Blenrep: EPAR \u2013 Product information"},{"key":"B20","unstructured":"Carvykti: EPAR \u2013 Product information"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004326","article-title":"ACCORD (Accurate Consensus Reporting Document): A reporting guideline for consensus methods in biomedicine developed via a modified Delphi","volume":"21","author":"Gattrell","year":"2024","journal-title":"PloS Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.33393\/grhta.2021.2245","article-title":"Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus","volume":"8","author":"Boccadoro","year":"2021","journal-title":"Glob Reg Health Technol Assess"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.12.012","article-title":"Multiple myeloma in Italy: An epidemiological model by treatment line and refractoriness status","volume":"25","author":"Mina","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1756247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:22:32Z","timestamp":1770960152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1756247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1756247"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1756247","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"1756247"}}